Watchlist Wire
Research Library · Maintained Bi-Weekly

The research library, built to last.

Every dossier on this page is permanent, search-indexed, and built from public filings. Risks are named where the data shows them. Compensation, where it exists, is disclosed under Section 17(b) on the report itself.

20
Active Dossiers
18
Roundup Editions
8
Research Briefings
100K+
Distribution Reach

Coverage ledger.

Twenty companies across Nasdaq, NYSE, NYSE American, OTC, the TSX-V, and the ASX. Each entry links to the full dossier.

Showing 20 of 20
AEYEActive
AudioEye Inc.
NASDAQ · Technology
40 consecutive quarters of record revenue. ARR at $40M. 131,000+ customers. DOJ enforcement tailwind.
Read dossier →
CXDOActive
Crexendo Inc.
NASDAQ · Technology
$68.2M FY2025 revenue, 12% growth, GAAP net income of $5.1M. $31.4M in cash, up 72.5%.
Read dossier →
CLPSActive
CLPS Technology Inc.
NASDAQ · Technology
$164.48M FY2025 revenue, 15.2% growth. U.S. revenue up 101.6% in H1 FY2026.
Read dossier →
BTBTActive
Bit Digital Inc.
NASDAQ · Technology
Revenue grew 140% to $108M in FY2024. Q3 2025 revenue $30.5M, up 33% year over year. HPC and AI cloud services.
Read dossier →
DPROActive
Draganfly Inc.
NASDAQ · Technology
$84M in cash after a 2025 equity raise. FY2025 revenue $7.73M, up 17.8%. 25 years in commercial drones.
Read dossier →
GFAIReview
Guardforce AI Co.
NASDAQ · Technology
$36.35M in stable revenue. GDM segment growing 18.1% in H1 2025. $25M cash position.
Read dossier →
RVSNMonitoring
Rail Vision Ltd.
NASDAQ · Technology
$22.4M cash. Binding MOU with Indian Railways via Sujan Ventures. Follow-on mining order from Latin America.
Read dossier →
COSMMonitoring
Cosmos Health Inc.
NASDAQ · Healthcare
Revenue growing, gross margins expanded from 7% to 15% in two quarters, cash operating burn down 95%.
Read dossier →
MDAIReview
Spectral AI Inc.
NASDAQ · Healthcare
$150M BARDA contract. DeepView FDA De Novo application submitted, determination pending. Revenue of $19.7M.
Read dossier →
ACONMonitoring
Aclarion Inc.
NASDAQ · Healthcare
$13.3M cash, zero debt, runway into 2028. NOCISCAN scan volume up 89% year over year.
Read dossier →
BSEMReview
BioStem Technologies
OTC Markets · Biotech
94% gross margins on restated net revenue. Seven consecutive profitable quarters. Clean FDA inspection.
Read dossier →
GLMDActive
Galmed Pharmaceuticals
NASDAQ · Biotech
$19.2M in cash against a market cap in the same range. Aramchol Phase 3 open-label showed 65% fibrosis improvement.
Read dossier →
NEOVActive
NeoVolta Inc.
NASDAQ · Clean Energy
Revenue grew from $0.6M to $6.7M in six quarters. 333% year-over-year growth in Q1 FY2026. American-assembled.
Read dossier →
ENTEFActive
ESE Entertainment Inc.
OTC / TSX-V · Entertainment
Bombee posted CAD $3.745M in a single quarter, 109% sequential growth. First positive EBITDA.
Read dossier →
WEBMonitoring
Web Travel Group Ltd.
ASX · Travel Technology
B2B online travel marketplace. WebBeds sources hotel inventory globally for travel-trade buyers.
Read dossier →
SNESReview
SenesTech Inc.
NASDAQ · Agriculture
Revenue up 20% to $2.2M in FY2025. Gross margin expanded 840 basis points to 62.5%. E-commerce up 88%.
Read dossier →
PAPLMonitoring
Pineapple Financial Inc.
NYSE American · Financial Services
Agent network grew 82% year over year. FY2025 gross billings $17.4M. Operating losses improved 22.9%.
Read dossier →
PRPBMonitoring
CC Neuberger Principal Holdings II
NYSE · SPAC
Special purpose acquisition company. A blank-check vehicle formed to identify and merge with a private business.
Read dossier →
XTIAMonitoring
XTI Aerospace Inc.
NASDAQ · Aerospace
$32.2M in cash as of September 2025, up from $4.1M in December 2024. Engineering services generating near-term revenue.
Read dossier →
AREBMonitoring
American Rebel Holdings Inc.
NASDAQ · Consumer
Going concern disclosed Q3 2025. Nine-month revenue down 25% year over year. $22.5M in debt. Risks named in full.
Read dossier →
No coverage matches that search. Clear it to see all 20 dossiers.

Research & compliance briefings.

How disclosed research works, what it costs, and why the coverage gap exists. Written for IR teams, CFOs, and investors doing diligence on the model itself.

Start hereResearch & Compliance
Is issuer-paid (sponsored) stock research legal?
Yes, when the compensation is disclosed. Section 17(b), the SEC enforcement record, and what compliant disclosure looks like.
Research & Compliance
Sponsored research vs. stock promotion.
They can look alike from the outside. The law treats them as opposites. The red flags and the markers, side by side.
Research & Compliance
What is a Section 17(b) disclosure?
The four things a compliant disclosure must convey, an annotated example, and the common ways disclosures fail.
Research & Compliance
Is issuer-paid research a conflict of interest?
Yes. That is exactly why the law requires disclosure. How the conflict is managed, and why disclosed research can still be credible.
Research & Compliance
How much does sponsored research cost?
There is no sticker price. What drives cost, the two pricing structures, and the red flags hiding in cheap offers.
Market Structure
Why analysts do not cover small-cap stocks.
The economics that created the coverage desert, why it keeps widening, and the realistic paths a small company has.
Market Structure
How can a micro-cap increase trading volume?
Liquidity follows visibility and structure. The inputs a company can influence, and the one lever it must never pull.
Market Structure
OTCQB vs. Nasdaq vs. NYSE American.
Listing standards, cost, and institutional access compared. Why uplisting fixes eligibility but not coverage.

The weekly roundup.

The market did something. Here is what it meant. Eighteen editions and counting, each with a micro-cap read on the week.

Latest edition & full archive
Start with the current week, then work backward through the ledger.
Open the roundup →
#018 #017 #016 #015 #014 #013 #012 #011 #010 #009 #008 #007 #006 #005 #004 #003 #002 #001

For public companies.

Coverage begins with an eligibility review against documented criteria. Companies that do not meet the standard are declined. Compensation is disclosed under Section 17(b) on every report.

Institutional Partnership → Coverage & distribution

For investors.

New dossiers and roundup editions, delivered when they publish. The research is free to read. The podcast covers the week in micro-caps.

Subscribe → Listen to the podcast
DisclosureWLW Holdings LLC may receive compensation from issuers whose securities are featured in research distributed through this platform. All compensation is disclosed per Section 17(b) of the Securities Act of 1933 on each respective report page. Nothing on this website constitutes investment advice. All investing involves risk.
© 2026 WLW Holdings LLC · Home · Roundup · Podcast · Institutional Inquiry · Subscribe